| 1. |
郭义恒, 于改革. 氟伐他汀治疗高尿酸血症肾病的Ⅰ期临床观察. 实用杂志, 2008, 22(4): 295-296.
|
| 2. |
党群, 王敬, 张莹. 高尿酸血症与高血压发生心血管事件的相关性探讨. 中华实用诊断与治疗杂志, 2006, 20(7): 505-506.
|
| 3. |
贾强, 娄姗姗, 孟召, 等. 性别和年龄与高尿酸血症及代谢综合征的关系. 中国全科医师, 2011, 10(8): 567-568.
|
| 4. |
李加平, 喻巧云. 高尿酸血症与代谢综合征的相关性研究. 国际检验医学杂志, 2011, 32(12): 1322-1325.
|
| 5. |
张秀娟, 辛长贵. 原发性高尿血症及痛风易感基因研究进展. 中华内分泌代谢杂志, 2011, 27(7): 611-612.
|
| 6. |
Masbernard A, Giudicelli CP. Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med, 1981, 59(65): 701-706.
|
| 7. |
van der Klauw MM, Houtman PM, Stricker BH, et al. Hepatic injury caused by benzbromarone. J Hepatol, 1994, 20(3): 376-379.
|
| 8. |
Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol, 2000, 32(5): 874.
|
| 9. |
Suzuki T, Suzuki T, Kimura M, et al. A case of fulminant hepatitis, possibly caused by benzbromarone. Nippon Shokakibyo Gakkai Zasshi, 2001, 98(4): 421-425.
|
| 10. |
叶任高, 陆再英. 内科学(第6版). 北京: 人民卫生出版社, 2006: 862.
|
| 11. |
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration, 2008.
|
| 12. |
胡政国, 刘家铎. 苯溴马隆与别嘌呤醇治疗高尿酸血症的疗效比较. 中国基层医药, 2010, 17(18): 2506-2507.
|
| 13. |
王雪君, 沈建军. 小剂量苯溴马隆与别嘌呤醇治疗高尿酸血60例疗效观察. 中国现代应用药学杂志, 2007, 24(4): 337-338.
|
| 14. |
赵占正, 肖静, 刘章锁. 苯溴马隆与别嘌呤醇治疗高尿酸血症/痛风的疗效观察. 中国误诊学杂志, 2005, 5(2): 281-282.
|
| 15. |
韩文娟, 钱培玲, 顾咏亮, 等. 苯溴马隆与别嘌醇治疗高尿酸血症临床效果对照. 上海医药, 2004, 25(10): 468-469.
|
| 16. |
Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis, 2009, 68(6): 892-897.
|
| 17. |
Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis, 1998, 57(9): 545-549.
|
